Commencement of Bio Park Operations and Entry into Oligonucleotides for Nucleic Acid Drug Raw Materials
First written in FY2025. 3 of 3 entries say "Advanced", first in FY2025. Latest entry: 2026-09-02.
1 other company's latest entry also says "Advanced".
- 2026-09-02AdvancedM&A and Subsidiary Changes
「The new company is being established to commercialize a CDMO business capable of providing an integrated service from raw materials for nucleic acid drugs through GMP manufacturing by leveraging these technologies and expertise. Going forward, we will develop a new building at our Koriyama Plant equipped with facilities and clean rooms capable of manufacturing nucleic acid drug active pharmaceutical ingredients, with the aim of providing one-stop services to domestic and overseas customers, including academia and pharmaceutical companies.」
The policy of entering the oligonucleic acid business for nucleic acid drug raw materials took concrete form through the establishment of a dedicated subsidiary, integrated services through GMP manufacturing, construction of a new building at the Koriyama Plant, and plans to provide one-stop services. - FY2026AdvancedAnnual report
「In addition to diagnostic oligonucleotides, SFC CO., LTD. aims to enter the CDMO business for oligonucleotides used as raw materials in nucleic acid drugs, a next-generation pharmaceutical product.」
Following the launch of Bio Park, the plan to enter the oligonucleotide business for nucleic acid drug materials was specified as a goal of entering the CDMO business based on diagnostic oligonucleotides. - FY2025AdvancedAnnual report
「SFC CO., LTD.'s Bio Park, a research and development and production facility, has begun operations, and the company aims to enter the oligonucleotide business for use as a raw material in nucleic acid drugs, a next-generation pharmaceutical product.」
SFC's Bio Park has begun operations, and its goal of entering the oligonucleotide business for use as a raw material in nucleic acid drugs was announced.